CYTOKINETICS INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data) (Unaudited)
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |
| Revenues: | ||||
| Research and development revenues | $463 | $378 | $1,547 | $3,358 |
| Milestone revenues | — | — | — | 2,500 |
| Total revenues | 463 | 378 | 1,547 | 5,858 |
| Operating expenses: | ||||
| Research and development | 84,612 | 82,532 | 245,779 | 245,147 |
| General and administrative | 56,652 | 40,111 | 152,976 | 129,498 |
| Total operating expenses | 141,264 | 122,643 | 398,755 | 374,645 |
| Operating loss | (140,801) | (122,265) | (397,208) | (368,787) |
| Interest expense | (8,928) | (7,136) | (28,763) | (21,142) |
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | (13,370) | (6,860) | (35,155) | (19,462) |
| Interest and other income, net | 17,054 | 6,839 | 36,520 | 20,043 |
| Change in fair value of derivative liabilities | 700 | — | 100 | — |
| Change in fair value of liabilities related to RPI Transactions | (15,200) | — | (15,000) | — |
| Net loss | $(160,545) | $(129,422) | $(439,506) | $(389,348) |
| Net loss per share — basic and diluted | $(1.36) | $(1.35) | $(4.00) | $(4.07) |
| Weighted-average number of shares used in computing net loss per share — basic and diluted | 117,685 | 96,071 | 109,932 | 95,666 |
| Other comprehensive (loss) gain: | ||||
| Unrealized gain on available-for-sale securities, net | 6,535 | 584 | 5,480 | 2,716 |
| Foreign currency translation adjustments | (126) | — | (83) | — |
| Comprehensive loss | $(154,136) | $(128,838) | $(434,109) | $(386,632) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.